Nanoparticles for drug delivery in cancer treatment

被引:627
作者
Haley, Barbara [1 ]
Frenkel, Eugene [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Harold Simmons Canc Ctr, Div Hematol Oncol, Dept Med, Dallas, TX 75390 USA
关键词
nanoparticles; urologic cancer; drug delivery;
D O I
10.1016/j.urolonc.2007.03.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nanoparticles (size in nanometer range) provide a new mode of cancer drug delivery functioning as a carrier for entry through fenestrations in tumor vasculature allowing direct cell access. These particles allow exquisite modification for binding to cancer cell membranes, the microenvironment, or to cytoplasmic or nuclear receptor sites. This results in delivery of high drug concentrations to the targeted cancer cell, with reduced toxicity of normal tissue. Several such engineered drugs are in clinical practice, including liposomal doxorubicin and albumin conjugate paclitaxel. The carrier mediated paclitaxel has already shown significant efficacy in taxane resistant cancers, an approach highly relevant in prostate cancer, where taxanes are the treatment of choice. Other modifications including transferrin receptor and folate receptor targeted drug delivery molecules are in study. This new technology provides many exciting therapeutic approaches for targeted high concentration drug delivery to cancer cells with reduced injury of normal cells. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:57 / 64
页数:8
相关论文
共 48 条
[1]   Control of tumour vascular permeability [J].
Baban, DF ;
Seymour, LW .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 34 (01) :109-119
[2]   Nanoparticles in cancer therapy and diagnosis [J].
Brigger, I ;
Dubernet, C ;
Couvreur, P .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) :631-651
[3]   Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells [J].
Calcabrini, A ;
Meschini, S ;
Stringaro, A ;
Cianfriglia, M ;
Arancia, G ;
Molinari, A .
HISTOCHEMICAL JOURNAL, 2000, 32 (10) :599-606
[4]  
Che YQ, 2006, INT J MOL MED, V17, P1027
[5]   Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel [J].
Desai, N ;
Trieu, V ;
Yao, ZW ;
Louie, L ;
Ci, S ;
Yang, A ;
Tao, CL ;
De, T ;
Beals, B ;
Dykes, D ;
Noker, P ;
Yao, R ;
Labao, E ;
Hawkins, M ;
Soon-Shiong, P .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1317-1324
[6]  
DESAI N, 2004, SANANTONIO BREAST CA
[7]   Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo [J].
Farokhzad, OC ;
Cheng, JJ ;
Teply, BA ;
Sherifi, I ;
Jon, S ;
Kantoff, PW ;
Richie, JP ;
Langer, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (16) :6315-6320
[8]   Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma [J].
Gill, PS ;
Wernz, J ;
Scadden, DT ;
Cohen, P ;
Mukwaya, GM ;
vonRoenn, JH ;
Jacobs, M ;
Kempin, S ;
Silverberg, I ;
Gonzales, G ;
Rarick, MU ;
Myers, AM ;
Shepherd, F ;
Sawka, C ;
Pike, MC ;
Ross, ME .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2353-2364
[9]   Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan [J].
Gordon, AN ;
Fleagle, JT ;
Guthrie, D ;
Parkin, DE ;
Gore, ME ;
Lacave, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3312-3322
[10]   Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer [J].
Gradishar, WJ ;
Tjulandin, S ;
Davidson, N ;
Shaw, H ;
Desai, N ;
Bhar, P ;
Hawkins, M ;
O'Shaughnessy, J .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7794-7803